Abstract: Anti-CD22 heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B cell disorders that are characterized by the expression of CD22.

Abstract: Provided herein are 4-aminoisoindoline-1,3-dione compounds having the following structure: wherein R, Ring A, and n are as defined herein, compositions comprising an effective amount of a 4-aminoisoindoline-1,3-dione compound, and methods for treating or preventing disorders.

Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R2a, R3, R3a, and R4, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R2a, R3, R3a, and R4, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein, R1 is hydrogen, alkyl of 1–6 carbon atoms, benzyl, alkylcarbonyl of 2–7 carbon atoms, or benzoyl; X is R2 is hydrogen, alkyl of 1–6 carbon atoms, benzyl, alkylcarbonyl of 2–7 carbon atoms, or benzoyl; R3 is hydrogen, alkyl of 1–6 carbon atoms, hydroxy, or alkoxy of 1–6 carbon atoms; a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a sulfate ester of the hydroxyl group at the 3- or 17-position when R1 or R2 is hydrogen, or a glucuronide of the hydroxyl group at the 3- or 17-position when R1 or R2 is hydrogen.

Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R2a, R3, R3a, and R4, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein are methods for the identification of effector molecules useful in the treatment of vulvovaginal atrophy. Methods of treating vulvovaginal atrophy comprising administering the effector molecules are also disclosed.

Abstract: The present invention provides a method of treating or inhibiting mucositis or radiation cystitis using an ER? selective ligand. The present invention also provides compositions, including pharmaceutical compositions, containing the ER? selective ligand and a traditional medicament for mucositis or radiation cystitis.

Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10, are as defined in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides methods for treating cognitive diseases or disorders and symptoms thereof with estrogen beta selective agonists.

Abstract: This invention provides estrogen receptor modulators of formula 1, having the structure wherein R, R?, A, A?, X, Y, and Y are as defined in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein R, R?, A, A?, X, Y, and Y are as defined in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides estrogen receptor modulators of formula 1, having the structure wherein, A is wherein R1, R2, R3, and R4, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R3, and R4, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R2a, R3, R3a, and R4, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: A plurality of genes modulated by estrogen or other agents, such as hormones or combinations of hormones, in various types of tissue is described. One embodiment of the disclosure relates to a plurality of genes, which demonstrates certain patterns of expression differing qualitatively or quantitatively, with and without exposure to estrogen and/or other hormone compositions. Methods of using these genes in identifying candidate agents that exert at least some of the biological effects of estrogen and/or other hormone, and pharmaceuticals and related therapies also is disclosed. The use of the plurality of genes in methods of monitoring, in gene chips and in kits also is disclosed.

Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein, R1, R2, and R3 are as defined in the specification; or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10, are as defined in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides estrogen receptor modulators of formula I, having the structure R1, R2, and R3 are as defined in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein, R1, R2, and R3 are as defined in the specification, or a pharmaceutically acceptable salt thereof.